stockrow
Friday 6 November 2026
Export SYRE’s income statement to Excel — free account
Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
104.18
7.59
+7.86%
Follow SYRE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (41.15%) | (25.96%) | (38.39%) | (32.14%) |
+8 more TTM periods Free account |
|
| (30.89%) | (19.03%) | (24.23%) | (21.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(23.39%) | (14.68%) | (23.80%) | (20.59%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.82) | (2.47) | (2.36) | (2.64) | |
Free Cash Flow |
(249.32) | (208.94) | (185.63) | (169.25) | |
| Other line items | |||||
Cash ROIC |
(11.74%) | (9.30%) | (13.14%) | (11.50%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.01 | 1.28 | 1.15 | 1.14 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.82) | (2.47) | (2.36) | (2.64) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026